Novanta (NOVT) has opened 2026 with Q1 revenue of US$257.7 million and basic EPS of US$0.52, setting the tone for how investors might assess the latest move in profitability. The company has seen quarterly revenue move from US$233.4 million in Q1 2025 to US$257.7 million in Q1 2026, while basic EPS shifted from US$0.59 to US$0.52 over the same period, and trailing twelve month EPS now sits at US$1.43 on revenue of just over US$1.0 billion. With a trailing net profit margin of 5.3% and a large US$27.7 million one off loss weighing on reported earnings, the story this quarter is less about headline growth and more about how resilient those margins look from here.

See our full analysis for Novanta.

With the headline results on the table, the next step is to see how these numbers line up against the widely held narratives around Novanta's growth potential, risk profile, and earnings quality.

Margins Under Pressure at 5.3%

• Over the last 12 months, Novanta generated about US$1.0b in revenue and US$53.7 million in net income (excluding extra items), which works out to a 5.3% net profit margin compared with 7.4% a year earlier.
• Analysts' consensus view expects higher profitability over time, yet the drop in trailing margin and the US$27.7 million one off loss create some friction with that optimism.
  • Consensus forecasts point to strong earnings growth of about 38.2% a year while revenue is expected to grow 5.9% a year. This implies that much of the expected progress comes from better margins rather than faster sales growth.
  • With trailing EPS at US$1.43 on US$1.0b of revenue and margins currently at 5.3%, investors will likely watch closely to see whether any margin lift shows up in future reported numbers before fully embracing the margin expansion story.

Lumpy EPS Trend vs Growth Story

• Quarterly EPS over the last five reported quarters has swung from US$0.12 in Q2 2025 to US$0.59 in Q1 2025 and now US$0.52 in Q1 2026, even as revenue moved within a narrower band between US$233.4 million and US$258.3 million.
• Supporters of the bullish narrative see strong structural demand in robotics, automation and medical devices as a base for more consistent earnings, yet the recent EPS pattern shows earnings are still quite sensitive to costs and one off items.
  • The consensus narrative highlights design wins and multi year contracts in areas like warehouse robotics and advanced surgery, which are expected to support above market revenue growth, but the last 12 months show only modest revenue movement from US$951.7 million to US$1.0b.
  • Bulls also point to plans for cost reduction and manufacturing shifts to improve resilience, while the recent one off loss of US$27.7 million and margin dip show that execution on those plans will be key to turning the growth story into steadier EPS.

On the back of these mixed margin and EPS signals, many bullish investors are looking closely at how the detailed bull case lines up with the latest numbers, and how much of the future growth story is already reflected in the price today. 🐂 Novanta Bull Case

Rich Valuation at 105.5x P/E

• The shares trade on a trailing P/E of 105.5x, compared with peer and industry averages of 58x and 26.1x, and the US$159.19 share price sits well above the DCF fair value estimate of US$104.77 and the US$157.00 analyst price target.
• Critics who lean bearish argue that this valuation leaves little room for setbacks in the growth plan, especially with recent profit pressure and one off charges still in the rear view mirror.
  • The trailing 12 month net profit margin moved from 7.4% to 5.3% and five year profit growth averaged 2.3% annually, which is much lower than the 38.2% annual earnings growth now expected, so the current multiple already prices in a clear step up in performance.
  • With revenue forecast to increase around 5.9% a year, bears question whether such a high P/E and premium to DCF fair value are justified if earnings do not track those ambitious margin and profit assumptions.

Skeptical investors who focus on valuation often want to see exactly how the cautious case frames these risks and what would need to go right for today’s price to hold up. 🐻 Novanta Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Novanta on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals on growth, margins and valuation, this is a moment to move quickly, review the underlying data, and form your own judgment using the 1 key reward and 1 important warning sign

Explore Alternatives

High volatility in EPS, a 5.3% net margin under pressure, and a 105.5x P/E suggest investors face meaningful risk if expectations are not met.

If that level of uncertainty feels uncomfortable, you can quickly compare today’s profile with companies screened for more resilient return potential using the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.